Clinical trial
A Randomized, Double-blind, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of BPI-7711 Capsule in Locally Advanced or Recurrent/Metastatic Treatment-naïve Non-small Cell Lung Cancer Patients With EGFR Mutation
Name
BPI-7711301
Description
A randomized, double-blind, positive controlled phase III study to evaluate the efficacy and safety of BPI-7711 capsule in locally advanced or recurrent/metastatic treatment-naïve non-small cell lung cancer patients with EGFR mutation
Trial arms
Trial start
2021-04-30
Estimated PCD
2023-12-31
Trial end
2024-02-29
Status
Active (not recruiting)
Phase
Early phase I
Treatment
BPI-7711
180 mg, oral, QD
Arms:
BPI-7711
Other names:
BPI-7711 capsule
Gefitinib
250 mg, oral, QD
Arms:
Gefitinib
Other names:
Iressa
Placebo Tablet
250 mg gefitinib placebo tablet, QD
Arms:
BPI-7711
Other names:
placebo
Placebo capsule
180 mg BPI-7711 placebo capsule, QD
Arms:
Gefitinib
Other names:
placebo
Size
369
Primary endpoint
Progression-free survival
up to approximately 16 months
Eligibility criteria
Inclusion Criteria:
* Histologically or cytologically confirmed non-small cell lung cancer.
* The ECOG score of performance status is 0-1.
* Locally advanced or recurrent metastatic NSCLC that has never received systemic treatment.
* According to RECIST1.1 criteria, there is at least 1 measurable lesion that has not been previously irradiated.
* Prior to enrollment, a central laboratory testing report has confirmed that the tumor has one of two common EGFR mutations positive that are sensitive to EGFR-TKI therapy, accompanied with or not accompanied with other EGFR mutation, with the exception of exon 20 insertion.
Exclusion Criteria:
* Previously received systemic treatment for locally advanced or recurrent metastatic cancer.
* Primary T790M mutation-positive patient.
* Previous interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonia requiring hormonal therapy, or any clinically proven active interstitial lung disease.
* Known active infections such as hepatitis B, hepatitis C, and human immunodeficiency virus.
* Local radiation therapy is carried out within 1 week; more than 30% bone marrow radiation therapy or extensive radiation therapy is performed within 4 weeks.
* ≤ 4 weeks from major surgery or ≤ 2 weeks from minor surgery.
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 369, 'type': 'ACTUAL'}}
Updated at
2023-09-05
1 organization
3 products
1 indication
Organization
Beta Pharma ShanghaiProduct
BPI-7711Indication
NSCLCProduct
GefitinibProduct
Placebo